AMAG Pharma (AMAG): Low Expectations Shift The Risk Reward To The Upside - Jefferies

August 11, 2016 7:48 AM EDT
Get Alerts AMAG Hot Sheet
Price: $24.70 +5.78%

Rating Summary:
    11 Buy, 10 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade AMAG Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Jefferies analyst, Eun Yang, reiterated her Buy rating on shares of AMAG Pharmaceuticals (NASDAQ: AMAG) noting that the Makena franchise (~60% of current revenue) has been disappointing since 3Q15 on missed sales/delays in line-extension strategies. The current share price abundantly reflects such frustration and assumes that Makena & Feraheme sales are going to zero following 02/18 & 06/23 exclusivity expiry. That may turn out to be the case or it may take a while for AMAG to regain investors' confidence but the analyst thinks that the risk/reward seems skewed to the upside .

The price target drops to $45.00 from $58.00 but reflects substantial upside from the current price of $25.51.

For an analyst ratings summary and ratings history on AMAG Pharmaceuticals click here. For more ratings news on AMAG Pharmaceuticals click here.

Shares of AMAG Pharmaceuticals closed at $22.31 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co

Add Your Comment